1
|
Liu CH, Zhang JJ, Zhang QJ, Dong Y, Shi ZD, Hong SH, He HG, Wu W, Han CH, Hao L. METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4. Cell Signal 2024; 113:110971. [PMID: 37979898 DOI: 10.1016/j.cellsig.2023.110971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 11/09/2023] [Accepted: 11/12/2023] [Indexed: 11/20/2023]
Abstract
Bladder cancer, the most common malignant tumor in the urinary system, exhibits significantly up-regulated expression of P3H4, which is associated with pathological factors. The objective of this study was to elucidate the underlying mechanism of P3H4 in bladder cancer. Initially, we analyzed P3H4 gene expression using the TCGA database and evaluated P3H4 levels in clinical samples and various bladder cell lines. P3H4 was found to be markedly overexpressed in bladder cancer samples. Subsequently, bladder cancer cells were transfected with shRNA targeting P3H4 (sh-P3H4), sh-METTL3, and P3H4 overexpression vectors (P3H4 OE). Viability, migration, and invasion of bladder cancer cells were assessed using CCK-8, wound healing, and transwell assays. Western blot analysis was performed to determine the levels of EMT-associated proteins, while RNA stability assays determined the half-life of P3H4. Knockdown of P3H4 resulted in inhibition of bladder cancer cell proliferation, migration, invasion, and EMT progression. Mechanistically, METTL3 was found to regulate the mRNA stability of P3H4 in bladder cancer. Moreover, overexpression of P3H4 reversed the inhibitory effects of METTL3 knockdown on bladder cancer cell behaviors. Stable cell lines were established by infecting EJ cells with lentiviral vectors containing sh-METTL3 or P3H4 OE. These cells were then implanted into the skin of BALB/c nude mice, and IHC analysis was used to analyze the expression levels of EMT-associated proteins. In vivo studies demonstrated that inhibition of METTL3 suppressed bladder cancer growth and EMT through P3H4. In conclusion, our findings suggest that METTL3 regulates the proliferation, metastasis, and EMT progression of bladder cancer through P3H4, highlighting its potential as a therapeutic target.
Collapse
Affiliation(s)
- Chun-Hui Liu
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China
| | - Jun-Jie Zhang
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China; Medical College of Soochow University, Suzhou 215123, Jiangsu, China
| | - Qian-Jin Zhang
- Department of Urology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian 223800, Jiangsu, China
| | - Yang Dong
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China; Medical College of Soochow University, Suzhou 215123, Jiangsu, China
| | - Zhen-Duo Shi
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China
| | - Si-Hao Hong
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China
| | - Hou-Guang He
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China
| | - Wei Wu
- Medical College of Soochow University, Suzhou 215123, Jiangsu, China
| | - Cong-Hui Han
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China; Medical College of Soochow University, Suzhou 215123, Jiangsu, China
| | - Lin Hao
- The Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China; Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China.
| |
Collapse
|
2
|
Xie J, Zhang Z. Recent Advances and Therapeutic Implications of 2-Oxoglutarate-Dependent Dioxygenases in Ischemic Stroke. Mol Neurobiol 2023:10.1007/s12035-023-03790-1. [PMID: 38041714 DOI: 10.1007/s12035-023-03790-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 11/08/2023] [Indexed: 12/03/2023]
Abstract
Ischemic stroke is a common disease with a high disability rate and mortality, which brings heavy pressure on families and medical insurance. Nowadays, the golden treatments for ischemic stroke in the acute phase mainly include endovascular therapy and intravenous thrombolysis. Some drugs are used to alleviate brain injury in patients with ischemic stroke, such as edaravone and 3-n-butylphthalide. However, no effective neuroprotective drug for ischemic stroke has been acknowledged. 2-Oxoglutarate-dependent dioxygenases (2OGDDs) are conserved and common dioxygenases whose activities depend on O2, Fe2+, and 2OG. Most 2OGDDs are expressed in the brain and are essential for the development and functions of the brain. Therefore, 2OGDDs likely play essential roles in ischemic brain injury. In this review, we briefly elucidate the functions of most 2OGDDs, particularly the effects of regulations of 2OGDDs on various cells in different phases after ischemic stroke. It would also provide promising potential therapeutic targets and directions of drug development for protecting the brain against ischemic injury and improving outcomes of ischemic stroke.
Collapse
Affiliation(s)
- Jian Xie
- Department of Neurology, Affiliated Zhongda Hospital, Research Institution of Neuropsychiatry, School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China
| | - Zhijun Zhang
- Department of Neurology, Affiliated Zhongda Hospital, Research Institution of Neuropsychiatry, School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China.
- Shenzhen Key Laboratory of Precision Diagnosis and Treatment of Depression, Department of Mental Health and Public Health, Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China.
| |
Collapse
|
3
|
Fang D, He Y, Yi Y, Mei J, Liu C. Hub gene associated with prognosis in bladder cancer is a novel therapeutic target. PeerJ 2023; 11:e15670. [PMID: 37601252 PMCID: PMC10439716 DOI: 10.7717/peerj.15670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 06/09/2023] [Indexed: 08/22/2023] Open
Abstract
Objective Bladder cancer is a clinical and social conundrum due to its high incidence and recurrence rate. It is urgent to find new targets for the diagnosis and treatment of bladder cancer and improve the prognosis and survival rate of bladder cancer patients. We sought a prognosis-related gene, built related models of evaluated bladder cancer and identified the function of the hub gene in bladder cancer. Methods We downloaded the data of bladder cancer patients from the TCGA database, and used differentially expressed genes (DEGs), copy number variation (CNV) and survival analysis to scan the hub genes associated with prognosis in bladder cancer. Then, multi-factor cox regression was used to obtain the bladder cancer prognosis correlation model. Then, we analyzed the relationship between the expression of hub gene and immune microenvironment of bladder cancer. The relationship between the expression of hub gene and prognosis in bladder cancer patients was verified by immunohistochemistry. Cell proliferation assay and drug sensitivity test in vivo were used to verify the inhibition of bladder cancer by targeted inhibitors. Results In bladder cancer, we screened seven hub genes (ACLY, CNP, NKIRAS2, P3H4, PDIA6, VPS25 and XPO1) associated with survival. Moreover, the multifactor regression model constructed with hub gene can well distinguish the prognosis of bladder cancer. Hub gene is mostly associated with immune microenvironment. Immunohistochemical results basically confirmed the importance of XPO1 in bladder cancer. Selinexor (an inhibitor of XPO1) could effectively inhibit the proliferation of bladder cancer in the cell proliferation experiments by CCK-8 assays and it could suppress the growth of bladder cancer in mouse bladder cancer model. Conclusions In this study, a prognostic model with seven hub genes has provided great help for the prognosis prediction of bladder cancer patients. And XPO1 is an important target affecting the prognosis of bladder cancer, and inhibition of XPO1 can effectively inhibit bladder cancer proliferation and growth.
Collapse
Affiliation(s)
- Dengpan Fang
- Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
- Department of Urology, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, China
| | - Yuanqiao He
- Center of Laboratory Animal Science, Nanchang University,, Nanchang, China
- Jiangxi Province Key Laboratory of Laboratory Animal, Nanchang, China
- Nanchang Royo Biotechnology, Nanchang, China
| | - Yun Yi
- The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Jiaqi Mei
- The First Clinical Medical College, Nanchang University, Nanchang, China
| | - Cundong Liu
- Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| |
Collapse
|
4
|
Sanya DRA, Onésime D. Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer. Hum Cell 2023:10.1007/s13577-023-00915-5. [PMID: 37209205 DOI: 10.1007/s13577-023-00915-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2023] [Accepted: 05/07/2023] [Indexed: 05/22/2023]
Abstract
Bladder cancer (BC) is featured as the second most common malignancy of the urinary tract worldwide with few treatments leading to high incidence and mortality. It stayed a virtually intractable disease, and efforts to identify innovative and effective therapies are urgently needed. At present, more and more evidence shows the importance of non-coding RNA (ncRNA) for disease-related study, diagnosis, and treatment of diverse types of malignancies. Recent evidence suggests that dysregulated functions of ncRNAs are closely associated with the pathogenesis of numerous cancers including BC. The detailed mechanisms underlying the dysregulated role of ncRNAs in cancer progression are still not fully understood. This review mainly summarizes recent findings on regulatory mechanisms of the ncRNAs, long non-coding RNAs, microRNAs, and circular RNAs, in cancer progression or suppression and focuses on the predictive values of ncRNAs-related signatures in BC clinical outcomes. A deeper understanding of the ncRNA interactive network could be compelling framework for developing biomarker-guided clinical trials.
Collapse
Affiliation(s)
- Daniel Ruben Akiola Sanya
- Micalis Institute, Diversité génomique et fonctionnelle des levures, domaine de Vilvert, Université Paris-Saclay, INRAE, AgroParisTech, 78350, Jouy-en-Josas, France.
| | - Djamila Onésime
- Micalis Institute, Diversité génomique et fonctionnelle des levures, domaine de Vilvert, Université Paris-Saclay, INRAE, AgroParisTech, 78350, Jouy-en-Josas, France
| |
Collapse
|
5
|
Hao L, Shi Z, Dong Y, Chen J, Pang K, He H, Zhang S, Wu W, Zhang Q, Han C. Efficient Delivery of P3H4 siRNA and Chlorin e6 by cRGDfK-Installed Polyarginine Nanoparticles for Tumor-Targeting Therapy of Bladder Cancer. Pharmaceutics 2022; 14:pharmaceutics14102149. [PMID: 36297587 PMCID: PMC9609145 DOI: 10.3390/pharmaceutics14102149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 09/28/2022] [Accepted: 09/30/2022] [Indexed: 12/24/2022] Open
Abstract
Purpose: Prolyl 3-hydroxylase family member 4 (P3H4) is a potent prognostic oncogene in bladder cancer (BC), and the inhibition of P3H4 suppresses BC tumor growth. This study aimed to evaluate the efficiency of P3H4 inhibition for BC tumor therapy via tumor-targeting nanoparticles. Methods and results: A linear polyarginine peptide (R9) was synthesized, azide-modified, and then assembled with cyclic pentapeptide cRGDfK. Chlorin e6 (ce6)-conjugated CH3-R9-RGD nanoparticles were prepared for the delivery of siP3H4 into T24 cells in vitro and BC tumors in vivo. Dynamic light scattering analysis identified that the optimum CH3-R9-RGD@siP3H4 molar ratio was 30/1. CH3-R9-RGD@ce6/siP3H4 nanocomposites decreased P3H4 expression and cell proliferation and promoted reactive oxygen species production, apoptosis, and calreticulin exposure in T24 cells in vitro. In vivo experiments showed that CH3-R9-RGD@ce6/siP3H4 nanocomposites caused pathological changes, suppressed BC tumor growth, promoted caspase 3 expression, and enhanced calreticulin exposure in tumor cells. Conclusions: The tumor-targeting CH3-R9-RGD nanocomposites encapsulating siP3H4 and ce6 might be an alternative therapeutic strategy or intravesical instillation chemotherapy for BC.
Collapse
Affiliation(s)
- Lin Hao
- Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, China
| | - Zhenduo Shi
- Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, China
- School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, China
| | - Yang Dong
- Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, China
- Medical College of Soochow University, Suzhou 215123, China
| | - Jiangang Chen
- Medical College of Soochow University, Suzhou 215123, China
- Department of Urology, The First People’s Hospital of Nantong City, Nantong 226001, China
| | - Kun Pang
- Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, China
| | - Houguang He
- Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, China
| | - Shaoqi Zhang
- Medical College of Soochow University, Suzhou 215123, China
| | - Wei Wu
- Medical College of Soochow University, Suzhou 215123, China
| | - Qianjin Zhang
- Medical College of Soochow University, Suzhou 215123, China
| | - Conghui Han
- Department of Urology, Xuzhou Central Hospital, Xuzhou 221009, China
- School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, China
- Medical College of Soochow University, Suzhou 215123, China
- Correspondence: ; Tel.: +86-516-83956711; Fax: +86-516-83840486
| |
Collapse
|
6
|
Fang C, Liang Y, Huang Y, Jiang D, Li J, Ma H, Guo L, Jiang W, Feng Y. P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR. Cancers (Basel) 2022; 14:cancers14133243. [PMID: 35805016 PMCID: PMC9264976 DOI: 10.3390/cancers14133243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 06/25/2022] [Accepted: 06/29/2022] [Indexed: 11/16/2022] Open
Abstract
Simple Summary Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer. Studies have shown that P3H4 is a key gene underlying the malignant progression of LUAD. A potential biomarker and therapeutic target, P3H4 is involved in various cancers, but its molecular mechanism in LUAD remains unclear. Based on a series of experiments, we found that it significantly promoted the metastasis and proliferation of LUAD in vivo and in vitro. Abstract Lung cancer is associated with the greatest number of cancer-related deaths worldwide. Lung adenocarcinoma (LUAD) accounts for 85% of all cases of lung cancer. Despite recent advances in treatment, the 5-year survival rate remains less than 15%. Thus, the diagnostic and therapeutic role of LUAD remain to be further studied. The prolyl 3-hydroxylase family member 4 (P3H4) is involved in various cancers, but little is known about its role in LUAD. Our study demonstrated that the P3H4 gene was upregulated in LUAD. Clinically, the expression of P3H4 was positively correlated with an advanced TNM stage and shorter survival. Functionally, P3H4 plays a significant role in the metastasis and proliferation of LUAD both in vitro and in vivo. Mechanistically, P3H4 might interact with EGFR to regulate the metabolic substances. Our study indicated that P3H4 is a critical gene in the malignant progression of LUAD and represents a potential biomarker and therapeutic target.
Collapse
Affiliation(s)
- Chen Fang
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; (C.F.); (Y.L.); (D.J.); (J.L.); (H.M.)
| | - Yingkuan Liang
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; (C.F.); (Y.L.); (D.J.); (J.L.); (H.M.)
| | - Yong Huang
- Department of Thoracic Surgery, Haimen People’s Hospital, Nantong 226100, China;
| | - Dong Jiang
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; (C.F.); (Y.L.); (D.J.); (J.L.); (H.M.)
| | - Jiaxi Li
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; (C.F.); (Y.L.); (D.J.); (J.L.); (H.M.)
| | - Haitao Ma
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; (C.F.); (Y.L.); (D.J.); (J.L.); (H.M.)
| | - Lingchuan Guo
- Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China;
| | - Wei Jiang
- Department of Thoracic Surgery, Dushu Lake Hospital Affiliated to Soochow University, Suzhou 215000, China
- Correspondence: (W.J.); (Y.F.)
| | - Yu Feng
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; (C.F.); (Y.L.); (D.J.); (J.L.); (H.M.)
- Correspondence: (W.J.); (Y.F.)
| |
Collapse
|